Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 23, 2018

A role of GPR55 in the antiepileptic properties of cannabidiol (CBD) (P2.277)

Benjamin J. Whalley, Michael Bazelot, Evan Rosenberg, Richard Tsien
First published April 9, 2018,
Benjamin J. Whalley
1GW Research Ltd Cambridge United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Bazelot
1GW Research Ltd Cambridge United Kingdom
2Reading School of Pharmacy, University of Reading Cambridge United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evan Rosenberg
3Neuroscience and Physiology, NYU School of Medicine New York NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Tsien
3Neuroscience and Physiology, NYU School of Medicine New York NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
A role of GPR55 in the antiepileptic properties of cannabidiol (CBD) (P2.277)
Benjamin J. Whalley, Michael Bazelot, Evan Rosenberg, Richard Tsien
Neurology Apr 2018, 90 (15 Supplement) P2.277;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: Evaluate CBD’s effect on GPR55 signalling.

Background: In CBD’s multimodal pharmacologic profile, one molecular target is antagonism of the orphan G-protein coupled receptor GPR55, activated by endogenous ligand lysophosphatidylinositol (LPI). Since LPI activation of GPR55 increases presynaptic Ca2+ and vesicular release at excitatory CA3-CA1 synapses, promoting the excitability of CA1 pyramidal neurons, antagonism of GPR55 may be a promising target for epilepsy management.

Design/Methods: Acute brain slices were taken from chronically epileptic animals following lithium-pilocarpine induced status epilepticus and non-epileptic controls (n=6–9/group). Whole-cell patch-clamp recordings of hippocampal CA1 pyramidal neurons and interneurons were made, and changes in LPI-mediated effects on frequency and waveform of miniature postsynaptic currents were examined in CBD-(10 μM) or CBD vehicle–treated slices. In vivo mouse models of acute seizure were used to assess the role of GPR55 in seizures and the effect of altered GPR55-mediated signaling upon CBD’s anticonvulsant potency. Results were compared using unpaired t-test and one way ANOVA statistical tests.

Results: Mean amplitude of miniature excitatory postsynaptic currents (mEPSCs) was decreased in epileptic vs non-epileptic slices (6.6±1.8 vs 14.9±5.6 pA; p<0.001). Mean mEPSC decay time constant was longer in epileptic vs non-epileptic slices (11.2±2.4 vs 14.5±0.9 ms; p<0.05), suggesting potential alterations in subunit composition of postsynaptic amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPARs). mEPSCs waveform changes in epileptic tissue were not affected by CBD (p>0.05). LPI mediated increase of mEPSCs frequency was potentiated in epileptic CA1 pyramidal cells (2.8±0.6) when compared to non-epileptic neurons (1.4±0.1, p<0.05); CBD fully inhibited this response.

Conclusions: These results show glutamatergic transmission at CA3-CA1 synapses is modified by epilepsy, potentially involving changes in AMPA receptor subunit composition. In addition, GPR55 function was enhanced by epilepsy in a manner that would worsen the disease state, but CBD remained fully potent in epileptic brains, suggesting a novel anticonvulsant mechanism of action of CBD.

Study Supported by:

GW Research Ltd

Disclosure: Dr. Whalley has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GW PHARMACEUTIALS (EMPLOYMENT). Dr. Whalley holds stock and/or stock options in GW PHARMACEUTICALS, which sponsored research in which Dr. Whalley was involved as an investigator. Dr. Bazelot has nothing to disclose. Dr. Rosenberg has nothing to disclose. Dr. Tsien has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Receive quarterly payments for serving on the HHMI Scientific Advisor Board.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (6)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise